[go: up one dir, main page]

TN2013000393A1 - Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase - Google Patents

Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase

Info

Publication number
TN2013000393A1
TN2013000393A1 TNP2013000393A TN2013000393A TN2013000393A1 TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1 TN P2013000393 A TNP2013000393 A TN P2013000393A TN 2013000393 A TN2013000393 A TN 2013000393A TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1
Authority
TN
Tunisia
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
inhibitors
derivatives
Prior art date
Application number
TNP2013000393A
Other languages
English (en)
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2013000393A1 publication Critical patent/TN2013000393A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention propose un composé de formule (I) ou un de ses sels pharmaceutiquement acceptables associés; dans laquelle G représente (II) ou (III); R1, R2 et R3 sont tels que décrite ici; leurs compositions pharmaceutiques associées; et leur utilisation associée dans le traitement de maladies, états ou troubles modulés par l'inhibition d'une (d') enzyme (s) acétyl-CoA carboxylase chez un animal.
TNP2013000393A 2011-04-22 2013-09-27 Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase TN2013000393A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
TN2013000393A1 true TN2013000393A1 (fr) 2015-01-20

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000393A TN2013000393A1 (fr) 2011-04-22 2013-09-27 Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase

Country Status (42)

Country Link
US (4) US8802688B2 (fr)
EP (1) EP2699576B1 (fr)
JP (1) JP5657174B2 (fr)
KR (1) KR101567659B1 (fr)
CN (2) CN106117205B (fr)
AP (1) AP3499A (fr)
AR (1) AR086198A1 (fr)
AU (1) AU2012245996B2 (fr)
CA (1) CA2831380C (fr)
CL (1) CL2013002794A1 (fr)
CO (1) CO6801757A2 (fr)
CR (1) CR20130464A (fr)
CU (1) CU24164B1 (fr)
CY (1) CY1117122T1 (fr)
DK (1) DK2699576T3 (fr)
DO (1) DOP2013000243A (fr)
EA (1) EA022375B1 (fr)
EC (1) ECSP13013038A (fr)
ES (1) ES2561452T3 (fr)
GE (1) GEP20166474B (fr)
GT (1) GT201300258A (fr)
HR (1) HRP20151397T1 (fr)
HU (1) HUE028602T2 (fr)
IL (1) IL228949A (fr)
MA (1) MA35061B1 (fr)
ME (1) ME02312B (fr)
MX (1) MX348860B (fr)
MY (1) MY162167A (fr)
NI (1) NI201300111A (fr)
NZ (1) NZ616156A (fr)
PE (1) PE20141187A1 (fr)
PH (1) PH12013501941A1 (fr)
PL (1) PL2699576T3 (fr)
PT (1) PT2699576E (fr)
RS (1) RS54526B1 (fr)
SG (1) SG194142A1 (fr)
SI (1) SI2699576T1 (fr)
TN (1) TN2013000393A1 (fr)
TW (1) TWI464171B (fr)
UA (1) UA107753C2 (fr)
UY (1) UY34027A (fr)
WO (1) WO2012143813A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
AR095036A1 (es) 2013-03-14 2015-09-16 Kalyra Pharmaceuticals Inc Compuestos analgésicos bicíclicos
BR112015028214A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
JP6434498B2 (ja) 2013-05-10 2018-12-05 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
CN105358152A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
MX2016002479A (es) 2013-09-12 2016-05-31 Pfizer Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
WO2015056782A1 (fr) 2013-10-17 2015-04-23 塩野義製薬株式会社 Nouveau dérivé d'alkylène
CN105814013A (zh) * 2013-12-12 2016-07-27 卡利拉制药公司 双环烷基化合物及合成
JP6741343B2 (ja) * 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
CA2892342C (fr) 2014-05-22 2016-11-01 Sylvain-Paul Morency Outil et methode de depalletisation de couche
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
RU2759916C2 (ru) * 2015-12-31 2021-11-18 Цзянсу Тасли Дии Фармасьютикал Ко., Лтд. Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
CN111094259B (zh) 2017-05-15 2023-08-11 里科瑞尔姆Ip控股有限责任公司 止痛化合物
RU2020116458A (ru) * 2017-11-21 2021-12-23 Пфайзер Инк. Кристаллическая соль 2-амино-2-(гидроксиметил)пропан-1,3-диола и 4-(4-(1-изопропил-7-оксо-1,4,6,7-тетрагидроспиро[индазол-5,4ʼ-пиперидин]-1ʼ-карбонил)-6-метоксипиридин-2-ил)бензойной кислоты
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
WO2024140923A1 (fr) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Inhibiteur de prmt5-mta
WO2024213044A1 (fr) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Dérivés de cycles fusionnés azacyclo-carbonyle et leur utilisation
WO2025036472A1 (fr) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Inhibiteur de prmt5 mta-coopératif spirocyclique

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (fr) 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
HUP0303376A3 (en) 2001-02-28 2007-08-28 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof
HRP20040716A2 (en) 2002-02-27 2005-02-28 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (fr) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. Derive spiro, procede de production et antioxydant
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
BRPI0510284A (pt) 2004-05-12 2007-10-30 Pfizer Prod Inc derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
BRPI0510273A (pt) 2004-05-25 2007-10-30 Pfizer Prod Inc derivados de tetraazabenzo[e]azuleno e análogos destes
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP1910375B1 (fr) 2005-07-19 2011-05-11 Merck Sharp & Dohme Corp. Derives de spirochromanone utilises en tant quinhibiteurs d'acetyle coenzyme a carboxylase
WO2007013691A1 (fr) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Composé spiro-cyclique
EP1951251B1 (fr) 2005-11-18 2010-12-29 Merck Sharp & Dohme Corp. Antagonistes du recepteur cgrp de spirohydatoin aryle
CA2641766A1 (fr) 2006-02-15 2007-08-23 Abbott Laboratories Nouveaux inhibiteurs d'acetyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabete, de l'obesite et du syndrome metabolique
SI2463283T1 (sl) 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza
US20090270435A1 (en) 2006-11-29 2009-10-29 Jeffrey Wayne Corbett Spiroketone Acetyl-CoA Carboxylase Inhibitors
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) * 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2008125945A2 (fr) 2007-04-12 2008-10-23 Pfizer Inc. Nouveaux derives de 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h.6h) carbaldehyde
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2009144555A1 (fr) 2008-05-28 2009-12-03 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
CA2729412A1 (fr) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Nouveaux acides spirochromanone carboxyliques
EP2310015A4 (fr) 2008-07-14 2011-10-26 Cropsolution Inc Modulateurs de l acétyl-coenzyme a carboxylase et procédés d utilisation associés
WO2010013161A1 (fr) 2008-07-29 2010-02-04 Pfizer Inc. Hétéroaryles fluorés
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
NZ595024A (en) 2009-03-11 2013-01-25 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
WO2010103438A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitués
CA2754523A1 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
EP2427448A1 (fr) 2009-05-08 2012-03-14 Pfizer Inc. Modulateurs du gpr119
EP2427450A1 (fr) 2009-05-08 2012-03-14 Pfizer Inc. Modulateurs de gpr119
JP2012528847A (ja) 2009-06-05 2012-11-15 ファイザー・インク Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
WO2011058473A1 (fr) * 2009-11-10 2011-05-19 Pfizer Inc. Inhibiteurs de n2-pyrazolospirocétone acétyl-coa carboxylase
PL2621493T3 (pl) * 2010-09-30 2017-01-31 Pfizer Inc. N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA

Also Published As

Publication number Publication date
CU20130126A7 (es) 2014-01-29
UA107753C2 (xx) 2015-02-10
US20120270893A1 (en) 2012-10-25
MA35061B1 (fr) 2014-04-03
MX348860B (es) 2017-06-30
US20140323730A1 (en) 2014-10-30
TWI464171B (zh) 2014-12-11
JP5657174B2 (ja) 2015-01-21
WO2012143813A1 (fr) 2012-10-26
AP2013007129A0 (en) 2013-09-30
CL2013002794A1 (es) 2013-12-27
US20150336958A1 (en) 2015-11-26
ECSP13013038A (es) 2014-01-31
EP2699576A1 (fr) 2014-02-26
PL2699576T3 (pl) 2016-05-31
CN103492388A (zh) 2014-01-01
MX2013012313A (es) 2014-01-31
IL228949A (en) 2016-11-30
AR086198A1 (es) 2013-11-27
SG194142A1 (en) 2013-11-29
CN106117205A (zh) 2016-11-16
CO6801757A2 (es) 2013-11-29
GT201300258A (es) 2015-06-02
US20150112068A1 (en) 2015-04-23
PT2699576E (pt) 2016-03-09
EA201391288A1 (ru) 2014-04-30
RS54526B1 (en) 2016-06-30
KR101567659B1 (ko) 2015-11-09
CU24164B1 (es) 2016-03-31
TW201305162A (zh) 2013-02-01
EP2699576B1 (fr) 2015-12-09
PH12013501941A1 (en) 2021-06-23
SI2699576T1 (sl) 2016-02-29
NZ616156A (en) 2014-08-29
GEP20166474B (en) 2016-05-10
KR20140015511A (ko) 2014-02-06
CA2831380C (fr) 2016-04-05
JP2014515755A (ja) 2014-07-03
PE20141187A1 (es) 2014-09-18
AU2012245996B2 (en) 2016-09-01
CA2831380A1 (fr) 2012-10-26
CY1117122T1 (el) 2017-04-05
HRP20151397T1 (hr) 2016-01-15
ME02312B (me) 2016-06-20
IL228949A0 (en) 2013-12-31
CN106117205B (zh) 2018-09-21
ES2561452T3 (es) 2016-02-26
EA022375B1 (ru) 2015-12-30
DOP2013000243A (es) 2013-12-31
US8802688B2 (en) 2014-08-12
UY34027A (es) 2013-04-05
CR20130464A (es) 2013-10-16
MY162167A (en) 2017-05-31
HUE028602T2 (hu) 2016-12-28
AU2012245996A1 (en) 2013-10-03
AP3499A (en) 2015-12-31
DK2699576T3 (en) 2016-02-15
NI201300111A (es) 2014-02-12

Similar Documents

Publication Publication Date Title
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA38461A1 (fr) Inhibiteurs de la voie de la kynurénine
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse
MA35347B1 (fr) Procedes therapeuiques